BEN-34712 / BenevolentAI - LARVOL DELTA

BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies (Businesswire) - "BenevolentAI...announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders